Accessibility Menu
Radnostix logo

Radnostix(OTC) INIS

Current Price$0.07
Market Cap$35.03MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1997)-99%
5 Year-42%
1 Year-38%
1 Month-5%
Radnostix last closing stock price
MetricPriceDate
Last closeUSD 0.072026-07-22
Radnostix stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.82%USD 0.072026-07-15
1 month-5.41%USD 0.072026-06-22
3 month-16.19%USD 0.082026-04-23
Year to date+8.1%USD 0.062025-12-31
1 year-37.54%USD 0.112025-07-22
3 year-22.11%USD 0.092023-07-21
5 year-42.43%USD 0.122021-07-23
Since inception-99.28%USD 9.251997-08-14

Radnostix Financials at a Glance

Market Cap

$35.03MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$12.21M

Net Income (TTM)

-$908.00B

EPS (TTM)

-$0.00

P/E Ratio

-16.15

Dividend

$0.00

Beta (Volatility)

0.63 (Low)

Price

$0.07

Volume

10,758

Open

$0.06

Previous Close

$0.07

Daily Range

$0.06 - $0.07

52-Week Range

$0.05 - $0.11

Estimated Earnings Date

May 13, 2026

INIS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Radnostix

Radnostix makes radioactive materials for hospitals and industry. Its products help doctors diagnose and treat diseases, and help companies test equipment. Hospitals use its drugs for thyroid treatment, while labs use its calibration tools to check machines.

Products and Services

  • Theranostics Products (52%): Radioactive drugs and chemicals for medical, research, and industrial use.
  • Calibration & Reference Products (33%): Tools for calibrating and testing medical imaging equipment, used by hospitals and labs.
  • Cobalt Products (13%): Cobalt-60 sources for cancer therapy and industrial testing, plus recycling services.
  • Medical Devices (2%): Automated capsule filling systems and lung ventilation devices, mainly for hospitals and clinics.
  • Fluorine Products (0%): High-purity fluoride gas samples for industry; facility project currently paused.

Growth and Expansion

  • Acquired Xenon System products from AMICI, Inc. in January 2025 to expand medical device offerings.
  • Formed joint ventures with Phantech/PhanQual and Alpha Nuclide Inc. to broaden calibration and reference products.
  • Partnered with ORANO LEA for non-medical calibration standards, increasing reach in industrial markets.
  • Completed a new calibration products facility in Idaho Falls in 2025, supporting future growth.
  • Expanded international sales channels in recent years, though most revenue remains U.S.-based.

What Makes Radnostix Stand Out

Radnostix is the only U.S. maker of a key thyroid drug, sodium iodide I-131. Its unique licenses allow handling of high-activity radioactive materials, supporting specialized products. The company’s just-in-time supply chain helps manage short-lived radioactive inventory.

Five Things You Need to Know

  • Revenue was $13.1 million in 2025, down 6% from 2024.
  • Theranostics Products made up 52% of 2025 revenue, but fell 15% year-over-year.
  • Calibration & Reference Products grew 21% in 2025 after supply chain recovery.
  • Operating loss was $956,187 in 2025, compared to a small profit in 2024.
  • Top three customers accounted for 31% of 2025 revenue, showing customer concentration risk.

Bottom Line

Radnostix has diversified across medical, industrial, and research markets. Its adaptability and specialized products help it navigate a complex, regulated industry.

AI Generated • Apr 16, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

45

CEO

Shahe Bagerdjian

Website

www.intisoid.com

Headquarters

Idaho Falls, ID 83401, US

INIS Financials

Key Financial Metrics (TTM)

Gross Margin

45.24%

Operating Margin

-18.03%

Net Income Margin

-7436334.68%

Return on Equity

-24706209.67%

Return on Capital

-0.00%

Return on Assets

-5282813.27%

Earnings Yield

-6.19%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$35.03MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

529.13M

Volume

10.76K

Avg. Volume

47.83K

Financials (TTM)

Gross Profit

$5.52M

Operating Income

-$2.20M

EBITDA

-$1.41M

Operating Cash Flow

$552.84K

Capital Expenditure

-$610.45K

Free Cash Flow

-$57.61K

Cash & ST Invst.

$1.35M

Total Debt

$8.79M

Radnostix Performance Analysis

Radnostix annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 11,181,98815.7%
20232023-12-31USD 12,267,3859.7%
20242024-12-31USD 13,899,76013.3%
20252025-12-31USD 13,070,336-6.0%
Radnostix sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3012.9%
Q32025-09-30-10.3%
Q42025-12-31-11.6%
Q12026-03-31-17.9%
Radnostix annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.00N/A
20232023-12-31USD -0.00N/A
20242024-12-31USD 0.00N/A
20252025-12-31USD -0.00N/A
Radnostix sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-50.0%
Q32025-09-30-33.3%
Q42025-12-31-430907400.0%
Q12026-03-31100.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$2.38M

-26.6%

Gross Profit

-$146.67K

-107.2%

Gross Margin

-6.17%

N/A

Market Cap

$35.03MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$854.48K

N/A

Employees

41

N/A

Net Income

-$1.35M

-1096.2%

EBITDA

-$1.18M

-1831.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$1.35M

-18.1%

Total Debt

$8.79M

+79.3%

Accounts Receivable

$1.27M

-24.7%

Inventory

$831.94K

+15.0%

Long Term Debt

$8.46M

+187.6%

Short Term Debt

$332.13K

-83.1%

Return on Assets

-52828.13%

N/A

Return on Invested Capital

-17.28%

N/A

Free Cash Flow

-$277.62K

-107.2%

Operating Cash Flow

-$72.44K

-1315.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PLNHPlanet 13 Holdings Inc.
$0.12+0.00%
VEXTFVext Science, Inc.
$0.17-6.89%
ETSTEarth Science Tech, Inc.
$0.15+7.14%
MRMDMariMed Inc.
$0.07+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.28-0.03%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.94+0.02%
INTCIntel
$102.62-0.03%
AALAmerican Airlines Group
$14.79-0.03%

Questions About INIS

What is the current price of Radnostix?

Radnostix is trading at $0.07 per share.

What is the 52-week range for Radnostix?

Over the past 52 weeks, Radnostix has traded between $0.05 and $0.11.

How much debt does Radnostix have?

As of the most recent reporting period, Radnostix reported total debt of $8.79M.

How much cash does Radnostix have on hand?

Radnostix reported $1.35M in cash and cash equivalents in its most recent financial results.

What is Radnostix’s dividend yield?

Radnostix does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services